SALUS promet s farmacevtskimi, medicinskimi in drugimi proizvodi, d.d., Ljubljana financials
SALUS promet s farmacevtskimi, medicinskimi in drugimi proizvodi, d.d., Ljubljana
Country: SI Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
4851000025STPWS61L07 Financial statements
(EUR, as reported — unscaled; 103 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €648.8M | €599.4M |
| Cost of sales | €575.3M | €539.3M |
| Gross profit | €73.5M | €60.2M |
| Other income | €727.1K | €894.8K |
| Distribution costs | €40.6M | €33.3M |
| Administrative expenses | €15.4M | €13.5M |
| Operating profit (EBIT) | €16.7M | €13.2M |
| Finance costs | €1.5M | €961.3K |
| Profit before tax | €16.7M | €13.1M |
| Profit for the year | €13.0M | €10.4M |
| — attributable to owners | €12.9M | €10.3M |
| — attributable to NCI | €163.1K | €128.5K |
| Total comprehensive income | €13.0M | €10.4M |
| Cash flow statement | ||
| Net cash from operating activities | €12.1M | €21.7M |
| Income taxes paid | -€2.4M | -€3.2M |
| Net cash from investing activities | -€4.0M | -€14.8M |
| Purchase of intangibles | €547.8K | €482.9K |
| Net cash from financing activities | -€14.3M | -€3.3M |
| Dividends paid | €7.4M | €7.3M |
| Proceeds from borrowings | €152.1M | €30.8M |
| Repayments of borrowings | €156.1M | €25.7M |
| Lease liability payments | €1.9M | €1.7M |
| Net change in cash | -€6.2M | €3.5M |
| Balance sheet | ||
| Total assets | €217.1M | €215.7M |
| Non-current assets | €62.6M | €64.4M |
| Property, plant & equipment | €42.1M | €43.4M |
| Intangible assets & goodwill | €7.7M | €6.7M |
| Current assets | €154.5M | €151.3M |
| Inventories | €61.9M | €55.5M |
| Trade & other receivables | €73.4M | €69.5M |
| Cash & equivalents | €16.5M | €22.7M |
| Total equity | €84.8M | €79.2M |
| Non-controlling interests | €1.8M | €1.7M |
| Non-current liabilities | €16.9M | €20.4M |
| Current liabilities | €115.5M | €116.1M |
| Trade & other payables | €104.9M | €105.1M |
| Deferred tax liabilities | €1.4M | €938.3K |
| Derived metrics | ||
| Operating margin | 2.6% | 2.2% |
| Net margin | 2.0% | 1.7% |
| Return on equity | 15.4% | 13.1% |
| Cash conversion ratio | 0.93× | 2.09× |
| Other reported items | ||
| Adjustments For Depreciation and Amortisation Expense | €8.0M | €5.7M |
| Adjustments For Income Tax Expense | €3.7M | €2.7M |
| Adjustments For Increase Decrease In Trade and Other Payables | €545.0K | -€21.4M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -€185.6K | -€80.9K |
| Adjustments For Provisions | -€66.3K | -€273.0K |
| Cash Advances and Loans Made To Other Parties Classified As Investing Activities | €250.0K | €340.0K |
| Cash and Cash Equivalents In Subsidiary Or Businesses Acquired Or Disposed2013 | €0 | €321.0K |
| Cash Flows From Used In Operations Before Changes In Working Capital | €25.0M | €18.7M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €0 | €9.5M |
| Cash Receipts From Repayment of Advances and Loans Made To Other Parties Classified As Investing Activities | €145.8K | €405.4K |
| Comprehensive Income From Continuing Operations Attributable To Noncontrolling Interests | €0 | €0 |
| Comprehensive Income From Continuing Operations Attributable To Owners of Parent | €13.0M | €10.4M |
| Current Accrued Expenses and Other Current Liabilities | €3.4M | €3.0M |
| Current Contract Liabilities | €707.8K | €1.5M |
| Current Financial Assets At Amortised Cost | €107.4K | €53.6K |
| Current Financial Liabilities At Amortised Cost | €5.1M | €6.3M |
| Current Prepayments and Other Current Assets | €2.3M | €2.5M |
| Current Receivables From Contracts With Customers | €206.3K | €235.0K |
| Current Tax Assets Current | €49.0K | €903.2K |
| Current Tax Expense Income | €4.2M | €2.6M |
| Current Tax Liabilities Current | €1.3M | €323.9K |
| Deferred Tax Assets | €195.3K | €108.9K |
| Deferred Tax Expense Income | -€542.6K | €97.5K |
| Dividends Received Classified As Investing Activities | €34.9K | €33.1K |
| Dividends Recognised As Distributions To Owners Per Share | €70.00 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €367 | €2.3K |
| Equity and Liabilities | €217.1M | €215.7M |
| Finance Income | €1.5M | €853.5K |
| Gains Losses On Exchange Differences On Translation Net of Tax | -€1.2K | €3.0K |
| Impairment Loss Impairment Gain and Reversal of Impairment Loss Determined In Accordance With IFRS9 | €32.2K | €138.8K |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | -€6.1K | -€3.9K |
| Increase Decrease In Working Capital | -€10.5M | €6.2M |
| Increase Decrease Through Change In Equity of Subsidiaries | €0 | €1.5M |
| Increase Decrease Through Transactions With Owners | -€7.4M | -€5.1M |
| Increase Decrease Through Transfers and Other Changes Equity | €0 | -€646.4K |
| Intangible Assets Other Than Goodwill | €9.3M | €10.8M |
| Interest Received Classified As Investing Activities | €90.6K | €40.7K |
| Investment Property | €1.6M | €1.7M |
| Investments In Associates | €92.7K | €76.3K |
| Investments In Subsidiaries | €0 | €0 |
| Issue of Equity | — | €1.4M |
| Issued Capital | €439.7K | €439.7K |
| Noncurrent Financial Assets At Amortised Cost | €487.7K | €434.5K |
| Noncurrent Financial Assets At Fair Value Through Profit Or Loss | €992.3K | €1.1M |
| Noncurrent Financial Liabilities At Amortised Cost | €14.1M | €18.2M |
| Noncurrent Provisions | €1.3M | €1.3M |
| Other Comprehensive Income | €13.0M | €10.4M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€71.1K | -€11.6K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€1.2K | €3.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€65.0K | -€7.7K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€1.2K | €3.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -€65.0K | -€7.7K |
| Other Expense By Function | €1.6M | €987.5K |
| Other Noncurrent Nonfinancial Assets | €217.7K | €121.0K |
| Other Noncurrent Nonfinancial Liabilities | €10.9K | €11.8K |
| Proceeds From Issuing Shares | €0 | €1.4M |
| Proceeds From Sales of Intangible Assets Classified As Investing Activities | €0 | €6.4K |
| Purchase of Financial Instruments Classified As Investing Activities | €86.1K | €0 |
| Reserve of Exchange Differences On Translation | -€21.6K | -€20.4K |
| Reserve of Remeasurements of Defined Benefit Plans | €82.7K | €155.9K |
| Retained Earnings Excluding Profit Loss For Reporting Period | €59.5M | €56.6M |
| Retained Earnings Profit Loss For Reporting Period | €12.9M | €10.3M |
Methodology
Every line item above is a fact tagged in SALUS promet s farmacevtskimi, medicinskimi in drugimi proizvodi, d.d., Ljubljana's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.